Search

Your search keyword '"Martinez-Climent, Jose A."' showing total 319 results

Search Constraints

Start Over You searched for: Author "Martinez-Climent, Jose A." Remove constraint Author: "Martinez-Climent, Jose A."
319 results on '"Martinez-Climent, Jose A."'

Search Results

1. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

2. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

3. Targeting the immune microenvironment in Waldenström macroglobulinemia via halting the CD40/CD40-ligand axis

4. Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation

6. The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma

7. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

8. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

11. Abstract 5117: Combined treatment with the epigenetic drug CM272 and an anti-BCL-XL proapoptotic drug sensitizes solid tumors to immune checkpoint blockade

12. Supplementary Data from Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death

13. Supplementary Figures S1-S7 from Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death

14. Data from Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death

17. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

18. Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma

19. DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features

20. Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)

21. OAB-033: Pre-clinical models of genetically heterogeneous multiple myeloma reveal mechanisms of immune escape and predict clinical immunotherapy outcomes

24. Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice

26. A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma

27. Preneoplastic somatic mutations including MYD88L²⁶⁵P in lymphoplasmacytic lymphoma

30. Preneoplastic somatic mutations including MYD88 L265P in lymphoplasmacytic lymphoma

32. Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death

33. Lymphoma-Derived IL-10 Is a Key Immunomodulatory Factor at the Tumor Microenvironment of Activated B-Cell Diffuse Large B-Cell Lymphoma and Influences In Vivo Responses to Immunotherapy

34. Comprehensive Characterization of the Bone Marrow Microenvironment Transcriptional Remodeling in the Progression from MGUS to Smoldering and Multiple Myeloma

35. Remodeling of the Immune Microenvironment By Oncogenic MYD88 Dictates Immunotherapy Responses across Indolent and Aggressive B-Cell Lymphomas

37. Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death

39. High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma

40. Waldenström's Macroglobulinemia (WM) Is Preceded By Clonal Lymphopoiesis Including MYD88 L265P in Progenitor B Cells

41. Discordances between Immunofixation (IFx) and Minimal Residual Disease (MRD) Assessment with Next-Generation Flow (NGF) and Sequencing (NGS) in Patients (Pts) with Multiple Myeloma (MM): Clinical and Pathogenic Significance

42. Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes

43. GeneChip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma

47. Molecular heterogeneity in MCL defined by the use of specificVH genes and the frequency of somatic mutations

49. The Pathogenesis of Multiple Myeloma (MM) Is Preceded By Mutated Lymphopoiesis and B Cell Oligoclonality That Persist in Patients with Negative Minimal Residual Disease (MRD)

50. Waldenström's Macroglobulinemia (WM) Is Preceded By Clonal Lymphopoiesis Including MYD88 L265P in Progenitor B Cells

Catalog

Books, media, physical & digital resources